v3.25.1
Segment information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Total research and development expenses $ 5,418,682 $ 6,401,279
General and administrative 4,363,004 2,173,115
Loss from operations (9,781,686) (8,574,394)
Interest expense (1,397,076) (1,503,697)
Interest income 633,093 919,984
Other Income, net [1] 8,602 8,104
Total other (expense), net (772,585) (575,609)
Income tax expense 0 0
Consolidated Net Loss (10,554,271) (9,150,003)
Personnel-related expenses [Member]    
Segment Reporting Information [Line Items]    
Total research and development expenses 4,182,905 3,860,827
General and administrative 2,299,835 1,080,022
Clinical expenses [Member]    
Segment Reporting Information [Line Items]    
Total research and development expenses 392,604 291,658
Quality assurance and regulatory approval expense [Member]    
Segment Reporting Information [Line Items]    
Total research and development expenses 86,755 60,967
Contract manufacturing, materials and components [Member]    
Segment Reporting Information [Line Items]    
Total research and development expenses 730,619 1,731,338
Facility-related and other expenses [Member]    
Segment Reporting Information [Line Items]    
Total research and development expenses 25,799 456,489
General and administrative 400,677 77,625
Professional services expenses [Member]    
Segment Reporting Information [Line Items]    
General and administrative 1,084,399 502,235
Corporate expense [Member]    
Segment Reporting Information [Line Items]    
General and administrative $ 578,093 $ 513,233
[1] Other Income (Expense) includes gain/ (loss) on foreign currency, and reimbursements of clinical trial expenses.